The treatment strategy of breast cancer varies based on molecular typing; however, as TNBC lacks expression of ER, PR, and HER-2, it has low hormone sensitivity, and the prognostic markers and therapeutic targets remain unknown. This evidence concerns the gene PGR and breast carcinoma.